CTOs on the Move

Massachusetts Medical Society

www.massmed.org

 
The Massachusetts Medical Society is the oldest, most distinguished and prestigious continuously operating state medical association in the United States and the world.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.massmed.org
  • 860, Winter Street
    Waltham, MA USA 02451
  • Phone: 800.322.2303

Executives

Name Title Contact Details
Jacqui Boire
Director, Technology Strategy and Planning Profile

Similar Companies

Fievet Pharmacy Inc

Fievet Pharmacy Inc is a Washington, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Santen

At Santen, we`re innovating therapies to improve the quality of life for patients worldwide. Our single focus in ophthalmology enables us to challenge unmet needs in the field—through passionate research, successful collaboration, and clarity of commitment. With over 120 years of investigative insight, Santen remains committed to the discovery, exploration, and development of ophthalmic therapies. Now, and into the future. As a global company, Santen is often expanding to accommodate new and evolving initiatives in ophthalmic research, regulatory management, production, marketing, or distribution. Our clinical development network now spans three continents, with centers in EMEA (Europe, the Middle East and Africa), Japan, and the United States.

Sandhills Center

Mental Health, Substance Use Disorder & I/DD Care for Central North Carolina Residents at Sandhills Center.

Falks Woodland Pharmacy

Falks Woodland Pharmacy is a Duluth, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharvaris

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.